Bryan and Margie Weingarten’s support for cancer prevention and medical innovation at Weill Cornell Medicine is helping connect groundbreaking research with the patients and families who depend on it.
That work will come into focus this October at the Innovations in Cancer Genetics Symposium, a three-day conference hosted by Weill Cornell Medicine’s Genetics and Personalized Cancer Prevention Program from October 15–17, 2026.
The symposium is expected to bring together approximately 300 people in person, with additional participants joining virtually, including physicians, researchers, patients, family members, and patient advocates. The gathering is designed to create a broader conversation around hereditary cancer, genetics, and personalized prevention.
For the Weingartens, the program represents an area of healthcare where research, education, and patient support intersect.
Their relationship with the Genetics and Personalized Cancer Prevention Program includes previous support for an oncology genetics social worker, an investment that recognizes an important reality of hereditary cancer care: patients and families often need guidance and support alongside medical expertise.
The October symposium will offer both scientific discussion and a more personal way to understand that experience.
On the evening of October 15, the program will feature a screening of Love, Danielle, followed by a live Q&A with lead actress Devin Sidell and executive producer Amy Byer Shainman. The film follows Danielle after she learns that she carries a BRCA1 gene mutation and faces a high risk of breast and ovarian cancer. With her older sister undergoing chemotherapy, she must consider difficult decisions about preventive surgery while navigating the effect of hereditary cancer on her family.
The story brings a human dimension to questions that can otherwise feel highly technical.
A genetic test can provide important information, but understanding what that information means can be complicated. Decisions about screening, prevention, and treatment can affect not only one person but an entire family. Patient advocates and healthcare professionals therefore play an important role in helping people navigate those decisions.
That broader perspective is consistent with the way the Weingartens have approached their support of Weill Cornell Medicine. Their philanthropy has focused on strengthening the people and programs working to improve healthcare, from medical research and women’s health to personalized cancer prevention.
Their earlier support of the genetics program and their continued relationship with Weill Cornell reflect a long-term interest in advancing care that combines scientific progress with attention to the individual patient.
The symposium provides an opportunity to bring that work together in one place. Researchers can share developments in the field, physicians can exchange perspectives on patient care, and patients and advocates can contribute experiences that help keep the discussion connected to real-world needs.
For Bryan and Margie Weingarten, that connection is an important part of meaningful medical philanthropy. Supporting innovation is not simply about funding the next discovery. It is also about helping institutions create the environment, expertise, and patient-centered programs needed to turn discoveries into better care.
As cancer genetics continues to evolve, collaboration will remain essential. The October symposium is one example of how Weill Cornell Medicine is bringing that collaboration together—and how sustained philanthropic support can help strengthen the work from research to patient care.
Related Posts
